Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals VRTX, Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares. Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment. For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsDeutsche BankRobyn Karnauskas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!